Search Featured Websites:
Feature your business, services, products, events & news. Submit Website.
Breaking Top Featured Content:
Feature your business, services, products, events & news. Submit Website.
Breaking Top Featured Content:
Actuate Therapeutics Announces Primary Endpoint Met In Phase 2 Study…
Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate in Combination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer
(PRWeb October 28, 2021)
Read the full story at https://www.prweb.com/releases/actuate_therapeutics_announces_primary_endpoint_met_in_phase_2_study_in_pancreatic_cancer/prweb18295347.htm
